Baatz Holger, Mirshahi Alireza, Puchta Joachim, Gümbel Hermann, Hattenbach Lars-Olof
Recklinghausen Eye Center, Recklinghausen, Germany.
Ocul Immunol Inflamm. 2006 Jun;14(3):185-7. doi: 10.1080/09273940600659740.
To report a case of toxoplasma retinochoroiditis reactivation in an immunocompetent patient under atovaquone therapy.
Case report.
A healthy woman with a history of bilateral toxoplasma retinochoroiditis since childhood presented with a reactivation of toxoplasma retinochoroiditis. Because earlier treatment regimens had either produced intolerable side effects and/or were deemed ineffective for the prevention of reactivation, the patient was started on atovaquone suspension (750 mg three times a day). After initial regression of the lesion and still under atovaquone therapy, the patient presented again five weeks later with worsened best-corrected visual acuity. Examination showed that the lesion had expanded again and more cells were present in the vitreous.
To our knowledge, this is the first report of a reactivation of toxoplasma retinochoroiditis in an immunocompetent patient under atovaquone therapy, possibly indicating tachyzoite resistance to atovaquone.
报告1例免疫功能正常的患者在接受阿托伐醌治疗时弓形虫视网膜脉络膜炎复发的病例。
病例报告。
一名自幼患有双侧弓形虫视网膜脉络膜炎的健康女性出现弓形虫视网膜脉络膜炎复发。由于早期治疗方案要么产生了无法耐受的副作用,和/或被认为对预防复发无效,该患者开始服用阿托伐醌混悬液(每日3次,每次750mg)。病变最初消退后,且仍在接受阿托伐醌治疗时,患者在5周后再次就诊,最佳矫正视力恶化。检查显示病变再次扩大,玻璃体内出现更多细胞。
据我们所知,这是首次报告免疫功能正常的患者在接受阿托伐醌治疗时弓形虫视网膜脉络膜炎复发,这可能表明速殖子对阿托伐醌耐药。